Navigation Links
PCMA Response to New York Times Article on Biotech Medicine Costs
Date:4/18/2008

WASHINGTON, April 18 /PRNewswire-USNewswire/ -- The Pharmaceutical Care Management Association (PCMA) issued the following statement today regarding a story to be published in tomorrow's New York Times:

"The New York Times has missed another opportunity to explain the real reasons behind increased spending on biotech medications. In the April 14, 2008 piece, 'Co-payments Soar for Drugs with High Prices,' the Times blames employers and plan sponsors for the high cost of biotech treatments. Then, in a piece dated tomorrow, 'Paid to Control Costs, Yet Pushing Some Prices Higher,' the Times blames high prices on those who dispense biotech products and manage related care. Meanwhile, both articles strangely downplay the role of those who actually set prices: the biotech manufacturers. They also ignore the fact that spending has increased because more patients have access to these life-saving medicines than ever before.

"Below are four fundamental issues the Times has either neglected or ignored:

-- First, the Times confuses those who price the biotech products (biotech manufacturers) with those who dispense them (specialty pharmacies). It's unfair to quote a source saying that benefit managers 'can raise prices at will' when manufacturers, not specialty pharmacies, set the prices for these products.

-- Second, the article virtually ignores that a key reason for high biotech prices is a legal loophole that protects biotech manufacturers from generic competition. Unlike traditional pharmaceuticals, there is no clear regulatory pathway for the FDA to approve generic versions of biotech products. For years, specialty pharmacies and pharmacy benefit managers (PBMs) have been fighting for legislation to allow biogenerics and competition to bring down biotech prices.

-- Third, the Times fails to report that more patients now have greater access to these products than ever before. That's good news, but it also costs more. Nearly 60 percent of the increase in spending on specialty biotech products last year was due to increased utilization, not price increases.

-- Fourth, the article distorts the role of limited distribution networks, which only apply to less than 2 percent of biotech prescriptions, specifically for treatments used by very small patient populations. These small populations often require extremely specialized care, such as infusions administered by highly trained nurses. This care prevents side-effects, reduces product wastage, and monitors possible inappropriate utilization.

Traditional wholesaler and retail networks are simply not equipped to provide this specialized and targeted care. To imply that limited distribution networks are somehow the cause of higher prices is grossly misleading.

In fact, the FDA requires that certain drugs be limited to one pharmacy due to special circumstances surrounding the medications."

PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 210 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D.


'/>"/>
SOURCE Pharmaceutical Care Management Association
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
2. Study identifies key player in the bodys immune response to chronic stress
3. Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.
4. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
5. Merck & Co., Inc. Response to Todays New York Medicaid Suit
6. Maternal depression and controlling behavior associated with increased stress response in infants
7. Family history of alcoholism affects response to drug used to treat heavy drinking
8. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
9. Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer
10. PET scans can accurately detect a breast tumors response to chemotherapy
11. DNA damage response confers a barrier for viral tumorigenesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2017)... ... ... Reassured For Life ( http://www.reassured.ca ), is now open. , “Reassured For ... Nerissa McNaughton. “I launched this firm because I know talking about life, accident, sickness, ... I make it easy. As a broker I have access to all the life ...
(Date:7/21/2017)... ... July 21, 2017 , ... "As a doctor of lung medicine managing ... available on the market," said an inventor from Center Valley, Pa. "My idea is ... patient." , He developed the patent-pending PLEURAL SAFE-t-STAT CATHETER KIT to offer an efficient ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Ellis Agency, an eastern Georgie ... Foundation in a community wide charity event with the goal of bringing in support ... local woman who lives with epilepsy, recently launched a charity campaign of her own ...
(Date:7/21/2017)... ... 21, 2017 , ... Adolfson & Peterson Construction (AP) along ... County Medical Examiners Facility located in Saint Paul, Minn. A single story, 10,688 ... to start in late 2017/early 2018. , Staffed by 20 full-time employees ...
(Date:7/21/2017)... Connecticut (PRWEB) , ... July 21, 2017 , ... Hospital ... from HealthCareMandA.com . The number of hospital acquisitions rose to 23 in the ... of 2017, and up 15% from the 20 announced deals in the year-ago second ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 2017 Zymo Research Corp., also known as ,The Epigenetics Company, ... aging in a precise manner using the myDNAge ™ test. Based ... professor of human genetics and biostatistics at the David Geffen School ... , Zymo Research,s proprietary DNAge ™ technology is used to analyze ... ...
(Date:7/11/2017)... 2017  Dr. Echenberg, founder of Echenberg Institute, is announcing a new ... suffer from painful intercourse and other painful pelvic pain conditions such as ... menopause. ... ... Sarasota, Florida -based start-up company, VuVatech LLC, fills a void in ...
(Date:7/10/2017)... 10, 2017  BDI Group subsidiary Pathway Purchasing ... services organization serving specialty pharmacies, home infusion companies ... four significant, value-added member programs designed to help ... reimbursement and improve access and affordability for patients ... Pathway has ...
Breaking Medicine Technology: